(Q40450653)

20 September 2017

title

Supplementation of sodium butyrate protects mice from the development of non-alcoholic steatohepatitis (NASH). (English)

1 reference

non-alcoholic steatohepatitis

20 September 2017

0 references

1 reference

Cheng Jun Jin

1

1 reference

20 September 2017

Cathrin Sellmann

2

1 reference

20 September 2017

Anna Janina Engstler

3

1 reference

20 September 2017

Doreen Ziegenhardt

4

1 reference

20 September 2017

Ina Bergheim

5

1 reference

20 September 2017

publication date

9 October 2015

1 reference

British Journal of Nutrition

20 September 2017

published in

1 reference

20 September 2017

volume

114

1 reference

20 September 2017

issue

11

1 reference

20 September 2017

page(s)

1745-1755

1 reference

Butyrate-producing probiotics reduce nonalcoholic fatty liver disease progression in rats: new insight into the probiotics for the gut-liver axis

20 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1017%2FS0007114515003621

SREBP-1, a membrane-bound transcription factor released by sterol-regulated proteolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0007114515003621

Tributyrin supplementation protects mice from acute ethanol-induced gut injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0007114515003621

Inhibition of histone deacetylase by butyrate protects rat liver from ischemic reperfusion injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0007114515003621

Butyrate promotes the recovering of intestinal wound healing through its positive effect on the tight junctions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0007114515003621

Butyrate protects liver against ischemia reperfusion injury by inhibiting nuclear factor kappa B activation in Kupffer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0007114515003621

Effects of sodium butyrate and its synthetic amide derivative on liver inflammation and glucose tolerance in an animal model of steatosis induced by high fat diet.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0007114515003621

Butyrate enhances intestinal epithelial barrier function via up-regulation of tight junction protein Claudin-1 transcription

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0007114515003621

Short-chain fatty acids activate AMP-activated protein kinase and ameliorate ethanol-induced intestinal barrier dysfunction in Caco-2 cell monolayers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0007114515003621

Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0007114515003621

Butyrate: implications for intestinal function

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0007114515003621

Expression of toll-like receptors 1-5 but not TLR 6-10 is elevated in livers of patients with non-alcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0007114515003621

The burden of liver disease in Europe: a review of available epidemiological data

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0007114515003621

Effects of oral butyrate application on insulin signaling in various tissues of chickens.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0007114515003621

Nonalcoholic fatty liver disease: a clinical review

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0007114515003621

Butyrate improves insulin sensitivity and increases energy expenditure in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0007114515003621

The role of liver fat and insulin resistance as determinants of plasma aminotransferase elevation in nonalcoholic fatty liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0007114515003621

IL-1 enhances expansion, effector function, tissue localization, and memory response of antigen-specific CD8 T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0007114515003621

IL-1β strikingly enhances antigen-driven CD4 and CD8 T-cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0007114515003621

Sodium butyrate decreases the activation of NF-κB reducing inflammation and oxidative damage in the kidney of rats subjected to contrast-induced nephropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0007114515003621

Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0007114515003621

In vitro and in vivo models of non-alcoholic fatty liver disease (NAFLD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0007114515003621

Sodium butyrate protects against toxin-induced acute liver failure in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0007114515003621

Beer Is Less Harmful for the Liver than Plain Ethanol: Studies in Male Mice Using a Binge-Drinking Model

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0007114515003621

Toll-like receptor 4 is involved in the development of fructose-induced hepatic steatosis in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0007114515003621

Antibiotics protect against fructose-induced hepatic lipid accumulation in mice: role of endotoxin

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0007114515003621

Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0007114515003621

Metformin protects against the development of fructose-induced steatosis in mice: role of the intestinal barrier function

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0007114515003621

Butyrate protects rat liver against total hepatic ischemia reperfusion injury with bowel congestion

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0007114515003621

Butyrate attenuates inflammation and lipolysis generated by the interaction of adipocytes and macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0007114515003621

7 January 2021

Female mice are more susceptible to nonalcoholic fatty liver disease: sex-specific regulation of the hepatic AMP-activated protein kinase-plasminogen activator inhibitor 1 cascade, but not the hepatic endotoxin response

1 reference

https://api.crossref.org/works/10.1017%2FS0007114515003621

7 January 2021

Role of the inducible nitric oxide synthase in the onset of fructose-induced steatosis in mice

1 reference

https://api.crossref.org/works/10.1017%2FS0007114515003621

7 January 2021

Toll-like receptors 1-9 are elevated in livers with fructose-induced hepatic steatosis

1 reference

https://api.crossref.org/works/10.1017%2FS0007114515003621

7 January 2021

Critical role of plasminogen activator inhibitor-1 in cholestatic liver injury and fibrosis

1 reference

https://api.crossref.org/works/10.1017%2FS0007114515003621

7 January 2021

Macrophage heterogeneity in liver injury and fibrosis

1 reference

https://api.crossref.org/works/10.1017%2FS0007114515003621

7 January 2021

Nutrition, intestinal permeability, and blood ethanol levels are altered in patients with nonalcoholic fatty liver disease (NAFLD)

1 reference

https://api.crossref.org/works/10.1017%2FS0007114515003621

7 January 2021

Butyrate enhancement of inteleukin-1β production via activation of oxidative stress pathways in lipopolysaccharide-stimulated THP-1 cells

1 reference

https://api.crossref.org/works/10.1017%2FS0007114515003621

7 January 2021

Role of tumor necrosis factor α (TNFα) in the onset of fructose-induced nonalcoholic fatty liver disease in mice

1 reference

https://api.crossref.org/works/10.1017%2FS0007114515003621

7 January 2021

Nonalcoholic fatty liver disease in humans is associated with increased plasma endotoxin and plasminogen activator inhibitor 1 concentrations and with fructose intake

1 reference

https://api.crossref.org/works/10.1017%2FS0007114515003621

7 January 2021

Inhibition of p38 mitogen-activated protein kinase attenuates butyrate-induced intestinal barrier impairment in a Caco-2 cell monolayer model

1 reference

https://api.crossref.org/works/10.1017%2FS0007114515003621

7 January 2021

10.1017/S0007114515003621

Identifiers

DOI

1 reference

20 September 2017

1 reference